Phase 2 N=30 Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (Part I) — 4; 20; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=66 Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain
Postoperative Pain · Acute Pain
Primary: Pharmacokinetic Profile of Serum Concentrations of Tapentadol After a Single Dose of Tapentadol Oral Solution in Adolescents (Age 12 to Less Than 18 Years). — 23.2…
Phase 1 N=34 Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers
Healthy
Primary: Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞) — 38.6; 61.3 ng*h/mL — p=1.0000
Phase 4 N=78 A Placebo-Controlled Study of Mirtazapine for PTSD
Anxiety · PTSD
Primary: Structured Interview of Posttraumatic Stress Disorder (SIP) — -7.61; -5.83 units on a scale
N/A N=104 Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate
Degeneration of Lumbar Intervertebral Disc
Primary: Posterolateral Fusion Success — 45 participants
Phase 2 N=56 Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Progression-free Survival Greater Than 6 Months — 31; 21 participants
Phase 2 N=749 A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.
Meningococcal Vaccine · rLP2086 · Repevax
Primary: Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen — 99.4; 99.4; 100.0; 100.0 percentage of participants
Phase 2 N=2,499 A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
Vaccines · Meningococcal Vaccines
Primary: Geometric Mean Titer (GMT) of Human Papillomavirus (HPV) Antigens — 451.8; 550.3; 892.9; 1084.3 titer
Phase 3 N=1,455 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1 — 76.9; 69.5 percentage of responders — p=0.001
Phase 1 N=1,236 A Brief Educational Intervention to Improve Traumatic Brain Injury (TBI) Screening Outcomes
TBI
Primary: mTBI Questionnaire — 5.38; 7.52 correct answers out of 10
N/A N=241 Telepsychology-Service Delivery for Depressed Elderly Veterans
Depression · Elderly
Primary: At Least a 50% Improvement From Baseline to Post-treatment on the Geriatric Depression Scale (GDS) — 17.6; 22.4; 22.0; 20.2 % participants with treatment response
Phase 3 N=441 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
Chronic Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 93.6; 96.4; 99.1; 99.1 percentage of participants…
Phase 1 N=44 Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)
Magnetic Resonance Imaging
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Infinity of Gadobutrol: Individual — 776 micromole*h/L
Phase 2 N=48 A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Mantle Cell Lymphoma
Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants
Phase 3 N=120 eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
Epilepsy
Primary: Retention at the End of the 21-week Treatment Period — 73.3 percentage of participants